Form 8-K - Current report:
SEC Accession No. 0001641172-25-023588
Filing Date
2025-08-13
Accepted
2025-08-13 17:16:45
Documents
14
Period of Report
2025-08-07
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 53199
  Complete submission text file 0001641172-25-023588.txt   265592

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ptix-20250807.xsd EX-101.SCH 3505
3 XBRL DEFINITION FILE ptix-20250807_def.xml EX-101.DEF 26531
4 XBRL LABEL FILE ptix-20250807_lab.xml EX-101.LAB 36469
5 XBRL PRESENTATION FILE ptix-20250807_pre.xml EX-101.PRE 25155
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5548
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 251212920
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)